arrow
M

Michele Montrone

istituto tumori “giovanni paolo ii”
H指数:22
被引数:1,433

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed” [Eur J Cancer 202, May 2024, 114006]

对“意大利接受一线帕博利珠单抗联合铂类/培美曲塞治疗的晚期非鳞状细胞肺癌患者的真实世界结局”的勘误 [Eur J Cancer 202, 2024年5月, 114006]

2026-06-270
PRE
Multidisciplinary Decision-Making and Integrated Strategies in Stage III Non-Small Cell Lung Cancer: Exploring Clinical Reasoning in Therapeutic Choices

III期非小细胞肺癌的多学科决策与综合策略:探究治疗选择中的临床推理

2026-05-190
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Corrigendum: The molecular tumor board as a step in cancer patient management: a southern Italian experience

勘误: 分子肿瘤委员会作为癌症患者管理的一个步骤: 意大利南部的经验

2024-10-250
OAAI
The molecular tumor board as a step in cancer patient management: a southern Italian experience

分子肿瘤委员会作为癌症患者管理的一个步骤: 意大利南部的经验

2024-09-111
OAAI
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

奥希替尼在具有罕见表皮生长因子受体突变的非小细胞肺癌中的活性: 回顾性观察性多中心研究 (ARTICUNO)

2024-06-011
OAAI
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024-05-013
PRE
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy
2024-01-183
OAAI
Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
2023-10-010
PRE